- Home
- OVV vs BMRN Comparison
OVV vs BMRN Comparison
Compare OVV & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OVV
- BMRN
- Stock Information
- Founded
- OVV 2020
- BMRN 1996
- Country
- OVV United States
- BMRN United States
- Employees
- OVV N/A
- BMRN N/A
- Industry
- OVV Oil & Gas Production
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- OVV Energy
- BMRN Health Care
- Exchange
- OVV Nasdaq
- BMRN Nasdaq
- Market Cap
- OVV 11.9B
- BMRN 13.7B
- IPO Year
- OVV N/A
- BMRN 1999
- Fundamental
- Price
- OVV $42.83
- BMRN $70.69
- Analyst Decision
- OVV Strong Buy
- BMRN Buy
- Analyst Count
- OVV 16
- BMRN 22
- Target Price
- OVV $56.53
- BMRN $94.00
- AVG Volume (30 Days)
- OVV 4.3M
- BMRN 1.4M
- Earning Date
- OVV 05-06-2025
- BMRN 04-23-2025
- Dividend Yield
- OVV 2.80%
- BMRN N/A
- EPS Growth
- OVV N/A
- BMRN 153.71
- EPS
- OVV 4.21
- BMRN 2.21
- Revenue
- OVV $8,943,000,000.00
- BMRN $2,853,915,000.00
- Revenue This Year
- OVV N/A
- BMRN $12.23
- Revenue Next Year
- OVV $6.30
- BMRN $9.90
- P/E Ratio
- OVV $10.17
- BMRN $32.04
- Revenue Growth
- OVV N/A
- BMRN 17.97
- 52 Week Low
- OVV $36.62
- BMRN $60.63
- 52 Week High
- OVV $55.95
- BMRN $94.85
- Technical
- Relative Strength Index (RSI)
- OVV 54.00
- BMRN 51.94
- Support Level
- OVV $41.35
- BMRN $69.60
- Resistance Level
- OVV $45.01
- BMRN $73.18
- Average True Range (ATR)
- OVV 1.28
- BMRN 1.63
- MACD
- OVV 0.35
- BMRN -0.23
- Stochastic Oscillator
- OVV 66.89
- BMRN 47.69
About OVV Ovintiv Inc. (DE)
Ovintiv is a North American oil and natural gas exploration and production company. It focuses on the exploration and development of oil, NGLs, and natural gas reserves. The company has three segments: USA Operations, Canadian Operations, and Market Optimization.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.